Détection de Clostridioïde difficile en 40 minutes*
45-minutes.* No Compromises.
Xpert vanA empowers clinicians to make critical decisions at the time it is needed most, thereby improving the quality of patient care while reducing cost.
Le besoin
According to the Centers for Disease Control and Prevention (CDC), about 30% of all healthcare-associated enterococcal infections are caused by Vancomycin-Resistant Enterococci (VRE).1 However, VRE can be even more prevalent in high risk groups, such as immunocompromised and ICU patients.
The human and financial impact of VRE is high2:
- Attributable mortality: 10%
- Extended length of stay: 6,2 days
- Incremental cost: $12 800
* With EAT (Early Assay Termination), for Positive Results
(1) CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.
(2) Carmeli Y, et al. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med. 2002 Oct 28;162(19):2223-8.
La solution
The CDC and SHEA have both published guidelines on how to reduce or eliminate healthcare associated infections.3,4 As a part of a quality infection control program, Cepheid's Xpert vanA provides:
- Rapid and accurate detection of the vanA gene most closely associated with VRE colonization
- Superior NPV required in a surveillance test
- Easy-to-use test with minimal hands-on time
(3) Siegel JD, et al. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control. 2007 Dec;35(10 Suppl 2):S165-93.
(4) Muto CA, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol. 2003 May;24(5):362-86.
Informations sur la commande
Xpert® vanA
Nombre de tests : 10
N° de réf. : GXVANA/B-CE-10
